Azimex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azimex

What is Azimex? — Overview and Key Facts

Azimex is a prescription-only brand-name drug that contains the active substance Azithromycin (INN), which belongs to the macrolide antibiotic class and is used to treat systemic bacterial infections. Azithromycin is a semi-synthetic compound, structurally derived from the earlier macrolide, erythromycin, but chemically modified to create the azalide subclass.

Property Description
Active Ingredient Azithromycin
Form Film-Coated Tablets, Oral Suspension, IV Solution
Pharmacological Class Azalide Macrolide Antibiotic
Primary Action Bacteriostatic (Inhibits bacterial protein synthesis)
Rx Status Prescription Drug (Rx)

What Type of Medicine is Azimex? (Classification and Origin)

Azimex is specifically classified as an azalide macrolide antibiotic, a category clinically recognized for its reliable efficacy against susceptible bacteria. The key differentiator of this class is its chemical structure, which grants it enhanced stability and pharmacokinetic properties, such as superior tissue penetration. Pharmacological studies confirm that this characteristic allows the active ingredient to accumulate in high concentrations within body tissues, which is particularly beneficial when managing deep-seated or chronic bacterial infections.

Azimex Composition and Available Forms

The product is a single-ingredient medicine, meaning it relies solely on Azithromycin for its therapeutic effects. The medicine is intended for systemic administration and is distributed in several forms, including film-coated tablets for oral use and sterile solutions for intravenous infusion. The availability of these distinct forms ensures healthcare providers can select the appropriate route of delivery, allowing for seamless transition from initial hospital-based treatment (IV) to patient self-administration (oral) for a complete course of therapy.

Primary Function: The General Purpose of Azimex

The fundamental function of Azimex is to serve as a broad-spectrum antimicrobial agent, working to halt the growth of bacterial pathogens. It acts as a bacteriostatic agent by interfering with the bacteria's ability to produce essential proteins necessary for growth and reproduction. This mechanism of action helps the patient's immune system overcome the bacterial threat, leading to the resolution of the systemic illness. The extended terminal half-life of Azithromycin, averaging 68 hours, is a factor that supports its overall purpose by allowing for a shorter duration of treatment compared to many other antibiotic types.

Regulatory References

  1. Azithromycin Mechanism of Action (StatPearls)

What side effects are possible with Azimex?

Possible Side Effects

Like all medicines, Azimex (azithromycin) can cause side effects, although not everybody gets them. The most common side effects are generally related to the gastrointestinal system and include nausea, vomiting, diarrhea, and abdominal pain.


Serious Side Effects

While rare, certain serious side effects require immediate medical attention. These include:

  • Allergic Reactions: Symptoms such as swelling of the face, tongue, or throat, severe rash, blistering or peeling skin (e.g., Stevens-Johnson syndrome or Toxic Epidermal Necrolysis), or difficulty breathing.
  • Liver Problems: Signs like jaundice (yellowing of the skin or eyes), dark urine, pale stools, or severe abdominal pain.
  • Heart Rhythm Changes: The drug has been associated with a potential risk of QT prolongation, which can lead to an irregular or fast heartbeat, dizziness, or fainting. This risk is greater in patients with existing heart conditions or low levels of potassium or magnesium.
  • Severe Diarrhea: Diarrhea that is severe, persistent, or contains blood or mucus may indicate a Clostridioides difficile infection, which can occur during or even months after treatment.

Important Safety Information (Contraindications and Warnings)

Before taking Azimex, inform your doctor if you have a history of an allergic reaction to azithromycin or any other macrolide or ketolide antibiotic. Use with caution in individuals with pre-existing heart rhythm problems (especially QT prolongation), liver impairment, or myasthenia gravis, as the medication may worsen these conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Adverse effects reported following the administration of Azimex (azithromycin) at doses higher than recommended are typically consistent with the drug’s known side effect profile. The most commonly reported manifestations of overdosage involve the gastrointestinal system, including nausea, diarrhea, and vomiting. Other potential risks associated with overdose include ototoxicity (hearing-related issues) and other gastrointestinal disturbances.

Management of a suspected overdose requires general symptomatic and supportive measures as clinically indicated. Regulatory information specifically notes that activated charcoal may be administered to help remove unabsorbed drug from the system.

When to Seek Immediate Medical Attention

Due to the risks associated with excessive dosing, immediate medical attention is required if an overdose is suspected. You must contact a healthcare professional, a hospital emergency department, or a regional Poison Control Centre immediately, even if no symptoms are currently present. This urgent action is required to ensure appropriate assessment and management of any potential severe effects, such as those impacting cardiac function or the liver.

Therapeutic Uses of Azimex

What Azimex Treats: Main Uses and Benefits

Azimex (Azithromycin) is a prescription antibiotic generally used to provide supports the patient during symptomatic phases in situations involving certain distressing symptoms. It is applied across therapeutic domains to manage the symptomatic burden associated with acute infections. It is commonly used to treat bacterial illnesses including infections of the ears, lungs (like pneumonia), sinuses, skin, throat, and reproductive organs (such as certain STIs).

This medicine is relevant for conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed. It helps in managing symptom clusters that may become intense or disruptive, such as high fever, persistent cough, and localized inflammatory pain.

“Azimex assists with maintaining daily comfort and contributes to easing the overall symptom load during difficult episodes of acute infection.”

Quick Fact: Relief for Acute Infection Symptoms Azimex is commonly used in clinical settings that involve acute or unstable symptom patterns, is relevant for easing symptoms related to inflammatory or irritative states in conditions like acute otitis media, bacterial sinusitis, and community-acquired pneumonia.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Azimex — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

  • Adults and pediatric patients 6 months of age and older [Source 1.2, 1.4].

Populations for whom use is not recommended (if applicable):

  • Patients with pneumonia judged inappropriate for oral therapy due to risk factors (e.g., cystic fibrosis, known bacteremia) [Source 1.4, 1.5].

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide antibiotic [Source 1.5].
  • Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin [Source 1.5].

Age-related eligibility rules:

  • Safety and effectiveness have not been established for most uses in pediatric patients under 6 months of age [Source 1.1, 1.2].
  • Use in neonates (up to 42 days of life) is associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) [Source 1.2].
  • Older Adults may be more susceptible to the risk of Torsades de Pointes arrhythmias [Source 1.1, 1.2].

Condition-specific eligibility rules:

  • Caution is required in patients with: Severe renal impairment (GFR < 10 mL/min), significant hepatic disease, Myasthenia Gravis (may exacerbate weakness), or known QT prolongation and other proarrhythmic conditions [Source 1.1, 1.2, 2.3, 2.5].

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Use should be only if clearly needed and when the benefit outweighs the possible risks [Source 3.1].
  • Lactation: Caution is advised, as the medicine is excreted in human milk [Source 2.4, 3.3].

Connection to the overall eligibility profile: Regulatory documents define eligible populations by stating clear contraindications (hypersensitivity, prior liver damage) and establishing age thresholds. The profile also mandates caution for populations with pre-existing conditions like severe cardiac risk factors, organ impairment, or Myasthenia Gravis, thereby setting precise constraints for who is permitted to use the medicine under its official labeling [Source 1.1, 1.5].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Azimex (Azithromycin) interactions are officially categorized based on effects that alter the drug's concentration or create combined effects with co-administered substances. The regulatory profile establishes specific constraints regarding concomitant use.

A significant pharmacodynamic interaction involves other drugs that prolong the QT interval, as co-administration imparts an additive risk of developing cardiac arrhythmias, including Torsades de pointes. This warrants careful consideration as an interaction-related constraint.

Pharmacokinetic interactions require strict monitoring. Azimex co-administration with the anticoagulant Warfarin may increase coagulation times, necessitating mandatory monitoring of Prothrombin Time or INR. Similarly, the HIV Protease Inhibitor Nelfinavir increases Azimex's serum concentrations, requiring close monitoring for known adverse reactions of Azimex.

While the total exposure to Azimex is generally unaffected by food, the maximum plasma concentration (Cmax) is known to increase. Conversely, Antacids containing Aluminum or Magnesium Hydroxide are documented to reduce Azimex's Cmax by approximately 24%. This pharmacokinetic effect leads to a specific timing-based interaction rule: these antacids must be administered approximately two hours before or after Azimex. Finally, official labeling includes population-specific notes, detailing that individuals with mild to moderate renal impairment experience only a minor, documented increase in Azimex exposure.

Mechanism of Action

Azimex exerts its primary effect by selectively targeting the 50S ribosomal subunit within susceptible bacteria, specifically binding to the 23S rRNA component. This molecular binding physically blocks the nascent peptide exit tunnel, thereby inhibiting protein translation and arresting the pathogen's growth and replication. . The physiological consequence of this mechanism is a bacteriostatic effect, which halts the proliferation of the bacterial population, which facilitates the action of the host's immune system against the arrested bacterial population. Beyond its antibacterial properties, the drug engages secondary mechanisms within the host by accumulating in immune cells and modulating signaling pathways. It interferes with the production of pro-inflammatory signals by suppressing the activation of transcription factors like NF-kappaB. This molecular action leads to the suppression of excessive pro-inflammatory cytokine release (e.g., IL-8) and subsequent reduction of neutrophil influx at sites of inflammation, which contributes to the reduction of host-mediated pathology. However, the mechanism is constrained by bacterial resistance, which involves acquired genes that either modify the ribosomal target or facilitate the active expulsion of the drug via efflux pumps.

Dosage and Administration Information

How to Use Azimex

Azimex (azithromycin) is administered orally via tablets, standard oral suspension, or extended-release suspension. The prescribed dosage and total duration of therapy vary, typically ranging from a single dose up to a five-day course, and sometimes once weekly for certain prevention protocols. Doses should be taken once daily at approximately the same time.

Administration Rules

Administration Rule Instruction
Timing in Relation to Meals Tablets and standard oral suspension may be taken with or without food. Extended-release oral suspension must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
Antacids Interaction The dose must be separated from antacids containing aluminum or magnesium by at least two hours to prevent reduced absorption.
Oral Suspension Preparation The oral suspension must be shaken well before each use. The correct dose must be measured using a proper dosing device. Single-dose packets must be mixed thoroughly with 60 mL (1/4 cup) of water and consumed immediately, with an additional 60 mL rinse.
Missed Dose If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and return to the regular schedule. Do not take a double dose to make up for a missed one.

Dosing Protocol Structure

The total dose and duration are strictly specified based on the condition being addressed. For example, some adult regimens involve 500 mg on Day 1, followed by 250 mg daily on Days 2 through 5. Pediatric dosing is determined by the child’s body weight and the specific infection, such as 10 mg/ kg once daily for three days. It is mandatory to complete the full duration of the course as prescribed, even if symptoms improve, to adhere to the official use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azimex

Evidence for Acute Respiratory and Sinus Infections

The research examined Azimex using short-term Randomized Controlled Trials (RCTs) and multicenter comparative studies for conditions such as Community-Acquired Pneumonia (CAP) and Acute Bacterial Sinusitis. Studies explored outcomes related to clinical success rates (the resolution of physical symptoms) and microbiological eradication. Findings describe patterns observed where short-course Azimex regimens measured clinical success rates in the observed populations. Follow-up was typically limited to 10 to 30 days after treatment ended. Increasing rates of antimicrobial resistance in common bacterial pathogens introduce uncertainty regarding the long-term relevance of some findings.

Evidence for Acute Otitis Media and Skin Infections

Azimex was evaluated in studies focused on Acute Otitis Media (AOM) in pediatric patients (≥ 6 months of age) and for uncomplicated Skin and Soft Tissue Infections (SSTIs) in adults. Comparative trials explored short-term symptom patterns, measuring outcomes such as clinical success and time to resolution. Research highlights measured changes in clinical success and side effect frequency. Some research describes a pattern of a higher measured risk of clinical treatment failure at one month for very short-course antibiotic regimens compared to the full courses of comparator antibiotics.

Studies Focused on Chronic Conditions and Long-Term Follow-up

Azimex was evaluated in long-term research scenarios, such as placebo-controlled trials for adult patients with Chronic Obstructive Pulmonary Disease (COPD) who experience frequent exacerbations. Research examined the overall frequency of acute exacerbations over periods extending up to a year. Findings describe patterns where long-term, low-dose administration was associated with a measured reduction in the rate of moderate or severe exacerbations compared to the placebo group. Long-term effects are not fully established outside of these specific maintenance studies.

What Remains Uncertain: Research Gaps and Study Limitations

Results apply only to the populations studied; for example, primary acute trials generally excluded the most severely ill patients, meaning data for certain groups remain insufficient. A critical, documented scientific limitation is the widespread issue of macrolide antimicrobial resistance, which can impact the relevance of older study findings. Follow-up durations were limited for the short-term treatment of most acute infections, meaning there is limited information for long-term outcomes.

Key Studies & References

  1. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections
  2. Zithromax (azithromycin) tablet label - FDA DailyMed (Used for approved indications and limitations)

Frequently Asked Questions (FAQ)

Common questions about Azimex (FAQ)


Q: How quickly does Azimex usually start working after taking it?

A: The active substance in Azimex is typically absorbed rapidly following administration. It quickly achieves high concentrations in body tissues, which is a factor in its therapeutic action. According to official product information, the time until an individual observes a clinical reduction in symptoms is generally variable and dependent on the specific infection being addressed.


Q: What is the role of Azimex compared to other common treatments in its class?

A: Azimex is classified as an azalide macrolide, a type of antibiotic with a distinct chemical structure compared to older macrolide treatments like erythromycin. This structural difference grants Azimex properties such as a prolonged half-life and the ability to achieve superior penetration into certain body tissues, which are factors in its overall therapeutic use.


Q: Is it common for people to feel tired while on Azimex?

A: Tiredness or fatigue is not listed among the most commonly reported gastrointestinal side effects, but it has been noted as a less common adverse effect in regulatory documents. Tiredness may be experienced; it is listed as a potential effect in official documents.


Q: Can Azimex cause dizziness or affect driving?

A: The use of Azimex has been associated with dizziness as a potential side effect. Official documents include warnings indicating that if dizziness occurs, caution is required when performing activities such as operating machinery or driving.


Q: What are the general research findings regarding Azimex and effectiveness?

A: Research, including short-term controlled trials for approved conditions like respiratory infections, has measured clinical success rates. Research evidence outlines patterns where measured clinical success rates were observed in the patient populations studied during these trials.


Q: Is there a generic version of Azimex available?

A: Azimex is the brand name for the active ingredient, which is azithromycin. According to drug regulatory records, the active substance azithromycin is also widely available as a generic medicine.


Q: How long does Azimex stay in the body after the last dose?

A: The active substance in Azimex has an extended terminal half-life of approximately 68 hours. Due to this characteristic, the substance remains in the body at detectable concentrations for an extended period, which may be up to two weeks, after the final dose.


Q: What are the storage requirements for Azimex?

A: Storage instructions include keeping the medicine in its original container away from light, heat, and moisture. Any unused or expired medicine, including remaining constituted liquid suspension, is recommended to be disposed of in accordance with local regulatory guidelines after the full course of therapy is completed.


Q: What are the official guidelines regarding Azimex use during lactation?

A: Official information indicates that the active ingredient in Azimex is known to be excreted into human milk. Official guidance advises caution, and use during lactation is described as being appropriate only when the potential benefit is considered to outweigh the possible risks.


Q: What happens if I stop taking Azimex early?

A: Regulatory warnings state that if the full prescribed course is discontinued prematurely, the infection may not be completely treated. The discontinuation of the full course prematurely is associated with a potential risk that the remaining bacteria could develop antibiotic resistance.


Q: Can Azimex be taken with common pain relievers like ibuprofen?

A: Azimex is not typically noted to have a formal drug-drug interaction warning with common over-the-counter pain relievers such as ibuprofen. The official interaction section focuses on other classes of medicines, such as anticoagulants and QT-prolonging drugs.


Q: Does Azimex interact with birth control pills?

A: Guidance from authoritative medical organizations indicates that Azimex is generally not expected to reduce the effectiveness of combined hormonal contraceptives, commonly known as birth control pills.


Q: Is it okay to drink coffee or caffeine while taking Azimex?

A: Regulatory documents do not contain any specific warnings or restrictions regarding the consumption of coffee or caffeine while an individual is taking Azimex.


Q: Are there any specific foods that should be avoided with Azimex?

A: Apart from the required timing constraint related to antacids containing aluminum or magnesium, no specific food items are listed as needing to be avoided in regulatory documents.


Q: Is Azimex safe for older adults (seniors)?

A: Official documents define a specific caution for older adults, noting that this population may have an increased susceptibility to the cardiac risk of QT interval prolongation and potential arrhythmia (an irregular heartbeat). This caution is particularly advised for those with existing cardiac risk factors.


Q: Does taking Azimex make me sensitive to the sun?

A: Increased sensitivity of the skin to sunlight, a reaction known as photosensitivity, has been reported as a potential adverse effect associated with Azimex.


Q: Is Azimex known to cause metallic taste?

A: An alteration in the sense of taste, medically referred to as dysgeusia, is a reported adverse effect associated with Azimex. This altered sensation may sometimes be perceived as a metallic or unusual taste.


Q: Can Azimex be used to prevent infections?

A: In addition to treating active bacterial infections, its approved uses include specific prevention protocols. For example, its approved uses include specific prevention protocols, such as for the prevention of Mycobacterium avium complex (MAC) in certain adult populations, as described in regulatory documents.


Q: Can Azimex be crushed or split?

A: Azimex tablets are generally not scored and should not be crushed or split. When a smaller dose or a liquid form is required, the oral suspension formulation is the form generally recommended by regulatory documents to ensure accurate dosing.

How should Azimex be stored and disposed of?

Storage Conditions for Azimex (Azithromycin)

Azimex requires strict adherence to labeled storage conditions to maintain efficacy. The tablets and the dry powder for suspension must typically be stored at or below 30 C and protected from light and moisture. The product must be stored in its original container and kept out of the sight and reach of children.

Suspension Stability

Once prepared, the standard liquid suspension has a limited stability period of 10 days when stored between 5 C to 30 C and must not be frozen. Certain extended-release suspensions have a shorter 12-hour stability limit and must not be refrigerated.

Disposal Instructions

Any remaining constituted suspension must be discarded after the full course of therapy is completed. All unused or expired medicine must be disposed of in accordance with local regulatory requirements, and should not be disposed of via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azimex found in:

A-Z Index: